Liver and Nonliver-Related Outcomes at 2 Years Are Not Influenced by the Results of the FIB-4 Test and Liver Elastography in a Real-Life Cohort of Patients with Type 2 Diabetes

Table 1

Baseline characteristics of patients.

Variable	N = 454, median (IQR)/n (%)
Age (years)	64 (56–71)
Male	236 (52%)
BMI (kg/m^2)	30.09 (26.45–34.34)
BMI < 25 (kg/m^2)	79 (17.4%)
BMI 25–30 (kg/m^2)	146 (32.2%)
BMI > 30 (kg/m^2)	229 (50.4%)
AST (IU/L)	22 (18–28)
ALT (IU/L)	24 (18–36)
GGT (IU/L)	29 (20–49)
ALP (IU/L)	71 (60–90)
PLT (×10^9/L)	245 (206–295)
TGL (mmol/L)	1.7 (1.2–2.5)
CHOL (mmol/L)	4.7 (4.0–5.6)
HDL (mmol/L)	1.2 (1.0–1.4)
LDL (mmol/L)	2.7 (2.1–3.5)
HbA1C (mmol/mol)	59 (50–76)
Hypertension	328 (72.2%)
Statin use (N = 448)	223 (49.1%)
Skin capsular distance (cm)	2.16 (1.80–2.51)
Use of XL probe	321 (70.7%)
VCTE (kPa)	5.6 (4.4–7.1)
VCTE ≤ 7.9 kPa	368 (81.1%)
VCTE > 7.9 kPa	86 (18.9%)
VCTE ≥ 9.6 kPa	45 (9.9%)
VCTE ≥ 11.5 kPa	33 (7.3%)
CAP (dB/m) (N = 453)	310 (256–347)
No steatosis (≤248 dB/m)	101 (22.2%)
Steatosis gr. I (249–268 dB/m)	29 (6.4%)
Steatosis gr. II (269–280 dB/m)	22 (4.8%)
Steatosis gr. III (>280 dB/m)	302 (66.5%)
FIB-4 (N = 433)	1.16 (0.84–1.53)
FIB-4 ≤ 1.3	269 (62.1%)
FIB-4 ≥ 2.67	14 (3.1%)

VCTE, vibration-controlled transient elastography; CAP, controlled attenuation parameter; BMI, body mass index; CHOL, total cholesterol; TGL, triglycerides; PLT, platelets.